The board of directors for Connecticut’s government-run venture capital fund unanimously approved a $291 million deal Thursday with Jackson Laboratory, a Maine nonprofit, to subsidize its development of a facility on the campus of the UConn Health Center.

The General Assembly passed legislation giving the venture fund, Connecticut Innovations, authority over the Connecticut Bioscience Collaboration Program at the October jobs session.

Gov. Dannel Malloy, who championed the deal with Jackson, will hold a signing ceremony for the legislation at noon.

Malloy signed the bill into law in November.

The Jackson Laboratory of Bar Harbor, Maine, does genetic research and develops mice with human diseases to be used in biomedical research. The Connecticut facility will branch out into genomic medicine, a new area for Jackson.

Jackson projects it will employ an average of 343.75 people in Connecticut over the next 20 years. State support of $291 million amounts to an annual subsidy of $42,327.27 per job.

Interest costs are expected to make the total value of the deal more than $400 million.

The CI board had to first approve operating procedures for the Connecticut Bioscience Collaboration Program. The procedures outline the 20 parts of an application for funding and the process the board will follow when awarding money through the program.

According to CI, Jackson was the only applicant for the funding.

For-profit companies could not apply for the subsidies because the legislation excludes them.

John Stafstrom Jr., a lawyer with Pullman & Comley who represented CI during negotiations with Jackson, told the board the deal gives CI certain rights to use research developed by Jackson.

According to Stafstrom, the agreement with Jackson includes a $145 million loan for the facility and $46.7 million for furniture, fixtures and equipment.

Stafstrom said the funding documents for the deal went through 12 versions before coming to the board for approval.

Department of Economic and Community Development Commissioner Catherine Smith, who chairs the CI board, said the agreement should remain exempt from public disclosure until it is signed because of trade secrets and “other competition.”

At least one director, Raphael Santiago, was unavailable for the meeting because he was traveling out of state. Some directors did not attend the meeting, but participated by phone.

Jackson also has a location in Sacramento and is part of a consortium that recently received approval to build a genetic engineering and research facility in New York City.

A plan to build in Florida similar to the current arrangement in Connecticut unraveled because the state could not provide $100 million in incentives to the lab.

Jackson announced the end of its Florida plan on June 3 and announced Connecticut’s interest in a location on Sept. 30.

The Malloy Administration’s recruitment of Jackson began idiosyncratically with chief of staff Tim Bannon reading about the doomed Florida plan at his family’s Maine vacation home near Bar Harbor.

The administration sees the recruitment of Jackson as an early success of its plan to invest $864 million in the University of Connecticut Health Center, a project known as Bioscience Connecticut.

“By investing in a smart, strategic project like Bioscience Connecticut, as we did in May, the state sent a loud and clear message around the world to companies and research institutes like Jackson Laboratory that we are ready, willing and able to be a partner in this up-and-coming industry,” Malloy said.